论文部分内容阅读
目的探讨替吉奥联合奥沙利铂治疗晚期结直肠癌的近期疗效和不良反应。方法选取2015年1月至2016年1月间内蒙古包头市包医第一附属医院收治的80例晚期结直肠癌患者,采用随机数字表法分为试验组和对照组,每组40例。试验组患者采用替吉奥联合奥沙利铂化疗方案治疗,对照组患者采用卡培他滨联合奥沙利铂化疗方案治疗。比较两组患者近期临床疗效、行为状态评分(KPS)和不良反应。结果试验组患者临床有效率为57.5%,KPS评分稳定率为72.5%,与对照组比较差异有统计学意义(P<0.05)。试验组患者骨髓抑制发生率和消化道反应发生率分别为80.0%和40.0%,对照组分别为97.5%和55.0%,两组比较差异有统计学意义(P<0.05)。结论替吉奥联合奥沙利铂治疗晚期结直肠癌患者,可显著提高近期疗效,降低不良反应发生率,值得临床推广。
Objective To investigate the short-term curative effect and adverse reaction of treatment of advanced colorectal cancer with tegaserod and oxaliplatin. Methods Eighty patients with advanced colorectal cancer admitted to the First Affiliated Hospital of Baotou Hospital, Baotou, Inner Mongolia from January 2015 to January 2016 were randomly divided into experimental group and control group with 40 cases in each group. Patients in the test group were treated with the combination of treatment with tiotropium and oxaliplatin, while those in the control group were treated with capecitabine and oxaliplatin chemotherapy. Short-term clinical efficacy, behavior status score (KPS) and adverse reactions were compared between the two groups. Results The clinical effective rate was 57.5% in the trial group and 72.5% in the KPS group, which was significantly different from the control group (P <0.05). The incidence of myelosuppression and the incidence of digestive tract reactions were 80.0% and 40.0% in the test group and 97.5% and 55.0% in the control group, respectively. There was significant difference between the two groups (P <0.05). Conclusion Treatment of patients with advanced colorectal cancer with tiotropium combined with oxaliplatin can significantly improve the short-term efficacy and reduce the incidence of adverse reactions, which deserves clinical promotion.